Mannin Research is a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular-related diseases using the TIE2 mechanism of action. Mannin’s TIE2 platform technology addresses a number of vascular-related diseases. Mannin is currently developing host-directed therapeutics to treat Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients.
Something looks off?